Ftse Mib
33.772,39
-0,04%
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
NASDAQ
19.572,60
1,03%
Bitcoin
96.628,28
-0,85%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Avalo Therapeutics Inc (AVTX) Avalo Therapeutics Inc (AVTX) Notizie

AVTX

Avalo Therapeutics (AVTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AVTX
DataOraFonteTitoloSimboloCompagnia
05/12/202413:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
14/11/202418:05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
12/11/202413:00GlobeNewswire Inc.Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement WarrantsNASDAQ:AVTXAvalo Therapeutics Inc
11/11/202413:00GlobeNewswire Inc.Avalo Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:AVTXAvalo Therapeutics Inc
07/11/202413:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AVTXAvalo Therapeutics Inc
07/11/202413:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVTXAvalo Therapeutics Inc
07/11/202413:00GlobeNewswire Inc.Avalo Reports Third Quarter 2024 Financial Results and Recent Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
08/10/202413:00GlobeNewswire Inc.Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis SuppurativaNASDAQ:AVTXAvalo Therapeutics Inc
08/10/202402:06Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AVTXAvalo Therapeutics Inc
04/09/202413:00GlobeNewswire Inc.Avalo Announces Participation in September Investor ConferencesNASDAQ:AVTXAvalo Therapeutics Inc
14/08/202423:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTXAvalo Therapeutics Inc
12/08/202413:00GlobeNewswire Inc.Avalo Reports Second Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
06/08/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AVTXAvalo Therapeutics Inc
05/08/202422:36Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AVTXAvalo Therapeutics Inc
29/07/202422:08Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
16/07/202422:17Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AVTXAvalo Therapeutics Inc
16/07/202413:00GlobeNewswire Inc.Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical OfficerNASDAQ:AVTXAvalo Therapeutics Inc
11/07/202422:12Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
24/06/202422:01GlobeNewswire Inc.Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal OfficerNASDAQ:AVTXAvalo Therapeutics Inc
17/06/202413:30GlobeNewswire Inc.Avalo to Present at the Oppenheimer Novel Targets in Immunology SummitNASDAQ:AVTXAvalo Therapeutics Inc
07/06/202413:01Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AVTXAvalo Therapeutics Inc
06/06/202422:03Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AVTXAvalo Therapeutics Inc
03/06/202413:20Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
13/05/202418:38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AVTXAvalo Therapeutics Inc
13/05/202413:30GlobeNewswire Inc.Avalo Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
02/04/202413:00GlobeNewswire Inc.Avalo Therapeutics Appoints Biotech Leaders to Board of DirectorsNASDAQ:AVTXAvalo Therapeutics Inc
29/03/202421:01GlobeNewswire Inc.Avalo Reports 2023 Financial Results and Provides Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
27/03/202421:01GlobeNewswire Inc.Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionNASDAQ:AVTXAvalo Therapeutics Inc
15/02/202403:13Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
27/12/202313:00GlobeNewswire Inc.Avalo Therapeutics Announces 1-for-240 Reverse Stock SplitNASDAQ:AVTXAvalo Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AVTX

La tua Cronologia

LATK
CELRUSDT
CelerToken
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network